Pages that link to "Q37258981"
Jump to navigation
Jump to search
The following pages link to A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer (Q37258981):
Displaying 12 items.
- Persistent androgen receptor addiction in castration-resistant prostate cancer (Q26777163) (← links)
- Evolution of ramucirumab in the treatment of cancer - A review of literature (Q28276412) (← links)
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancer (Q38797560) (← links)
- Antibody therapeutics for treating prostate cancer: where are we now and what comes next? (Q39500185) (← links)
- In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor (Q41838419) (← links)
- A critical review on ramucirumab in the treatment of advanced urothelial cancer. (Q47787312) (← links)
- Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. (Q50938980) (← links)
- Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. (Q53700821) (← links)
- Treating non-responders: pitfalls and implications for cancer immunotherapy trial design (Q90324850) (← links)
- Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89Zr-labeled ramucirumab (Q90620413) (← links)
- Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials (Q92802225) (← links)
- AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway (Q94475957) (← links)